Table 2

Relation between biomarkers of vascular inflammation, myocardial necrosis, platelet activation and a composite of all-cause mortality and non-fatal MI during 4-year follow-up

HR and 95% CI
Patients receiving placebo (N=544)All patients (N=1090)
BiomarkerResultEvents at 4-year follow-up, % (Kaplan–Meier estimate)*UnadjustedAdjusted, for all other biomarkers onlyAdjusted, for all other biomarkers and clinical characteristicsUnadjustedAdjusted, for all other biomarkers onlyAdjusted, for all other biomarkers and clinical characteristics
PlaceboAll patients
TnT>0.01 μg/l23.520.32.2 (1.3 to 3.6)2.3 (1.4 to 3.9)2.0 (1.1 to 3.6)2.1 (1.4 to 3.0)2.1 (1.4 to 3.0)1.8 (1.2 to 2.6)
≤0.01 μg/l11.611.1111111
hsCRP>10 mg/l23.020.31.6 (1.0 to 2.4)0.9 (0.5 to 1.4)0.8 (0.5 to 1.3)1.6 (1.2 to 2.3)1.1 (0.8 to 1.6)1.0 (0.7 to 1.5)
≤10 mg/l15.313.5111111
sCD40L>5.0 μg/l21.818.71.6 (1.1 to 2.4)1.5 (0.9 to 2.3)1.5 (0.9 to 2.3)1.4 (1.0 to 1.8)1.3 (0.9 to 1.7)1.2 (0.9 to 1.6)
≤5.0 μg/l15.115.0111111
IL-10<3.5 ng/l21.720.81.7 (1.1 to 2.6)1.6 (1.1 to 2.5)1.7 (1.1 to 2.7)1.7 (1.1 to 2.5)1.6 (1.1 to 2.5)1.7 (1.1 to 2.6)
≥3.5 ng/l13.714.2111111
Myeloperoxidase>350 μg/l24.621.41.7 (1.1 to 2.5)1.8 (1.2 to 2.9)1.6 (1.0 to 2.6)1.5 (1.1 to 2.1)1.5 (1.1 to 2.1)1.5 (1.1 to 2.1)
≤350 μg/l15.914.9111111
PAPP-A>12.6 mIU/l22.419.71.6 (1.1 to 2.5)1.3 (0.8 to 1.9)1.2 (0.8 to 1.9)1.4 (1.1 to 1.9)1.1 (0.8 to 1.6)1.1 (0.8 to 1.6)
≤12.6 mIU/l14.714.1111111
PlGF>27 ng/l27.624.02.6 (1.7 to 3.9)2.4 (1.6 to 3.7)2.4 (1.4 to 4.1)2.2 (1.6 to 3.0)2.0 (1.4 to 2.8)1.9 (1.3 to 2.8)
≤27 ng/l11.311.5111111
  • Non-significant results are reported in Italics.

  • * Events include all-cause mortality and non-fatal myocardial infarction (MI).

  • All biomarkers as presented in this table.

  • All biomarkers as presented in this table, as well as index diagnosis, age, gender, smoking, diabetes mellitus, hypertension, left ventricular ejection fraction and hypercholesterolaemia, ST-depression, ST-elevation or T-wave changes on the admittance ECG and history of myocardial infarction, peripheral vascular disease, chronic heart failure or previous percutaneous coronary intervention.

  • TnT, troponin-T; hsCRP, high-sensitivity C-reactive protein; IL-10, interleukin-10; PAPP-A, pregnancy-associated plasma protein A; PlGF, placental growth factor; sCD40L, soluble CD40 ligand.